Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Key Points: Active Ingredient: Tirzepatide Administration: Once-weekly injectable FDA Approval: Approved for diabetes management in 2022 Benefits: Significantly lowers HbA1c levels, promotes weight loss, and has demonstrated effectiveness in improving other metabolic parameters
Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)]
Medical eligibility is determined only after review by an independent licensed healthcare provider
Y.WightT
The cysteine residue of GSH can donate Hand e to radicals
